Cystic Fibrosis – Pipeline Assessment and Market Forecasts to 2017

GlobalData’s pharmaceutical and healthcare report, “Cystic Fibrosis - Pipeline Assessment and Market Forecasts to 2017” is an essential source of information and analysis on the global cystic fibrosis market. The report identifies the key trends shaping and driving the global cystic fibrosis market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shifts in the positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global cystic fibrosis sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

Companies Mentioned

Cystic Fibrosis Foundation Therapeutics, Inc.
Pharmaxis Ltd
Gilead Sciences, Inc
Vertex Pharmaceuticals, Inc
AstraZeneca
PARI Pharma
[Fade out the market survey infos]

1 Table of contents 3
1.1 List of Tables 5
1.2 List of Figures 5
2 Cystic Fibrosis: Introduction 6
2.1 GlobalData Pipeline Report Guidance 6
3 Cystic Fibrosis: Market Characterization 7
3.1 Market Overview 7
3.2 Cystic Fibrosis Market Size 7
3.3 Cystic Fibrosis Market Forecast and CAGR 8
3.4 Drivers and Barriers for Cystic Fibrosis Market 9
3.4.1 Drivers for Cystic Fibrosis Market 9
3.4.2 Barriers for Cystic Fibrosis Market 10
3.5 Opportunity and Unmet Need 10
3.6 Key Takeaway 11
4 Cystic Fibrosis Market: Competitive Assessment 12
4.1 Overview 12
4.2 Strategic Competitor Assessment 12
4.3 Product Profile for the Major Marketed Products in Cystic Fibrosis Market 13
4.3.1 Tobi (Tobramycin Inhalation Solution) 13
4.3.2 Pulmozyme (Dornase Alfa) 14
4.3.3 Zenpep (Pancrelipase capsules) 15
4.3.4 Cayston (Aztreonam for Inhalation Solution) 15
4.3.5 Colistimethate sodium (Colistin, Colomycin Injection, Promixin, Coly-Mycin M) 16
4.4 Key Takeaway 18
5 Cystic Fibrosis: Pipeline Assessment 19
5.1 Overview 19
5.2 Strategic Pipeline Assessment 19
5.2.1 Technology Trends Analytic Framework 19
5.3 Cystic Fibrosis – Promising Drugs under Clinical Development 20
5.4 Molecule Profile for Promising Drugs under Clinical Development 21
5.4.1 Denufosol Tetrasodium Inhalation Solution (INS37217) 21
5.4.2 VX-770 22
5.4.3 Bronchitol 23
5.4.4 Ataluren (PTC-124) 23
5.5 Cystic Fibrosis – Clinical Pipeline by Mechanism of Action 24
5.6 Cystic Fibrosis – Pipeline by Clinical Phases of Development 25
5.6.1 Cystic Fibrosis – Phase III Clinical Pipeline 25
5.6.2 Cystic Fibrosis – Phase II Clinical Pipeline 26
5.6.3 Cystic Fibrosis – Phase I Clinical Pipeline 28
5.6.4 Cystic Fibrosis – Preclinical Pipeline 29
5.6.5 Cystic Fibrosis – Discovery Pipeline 29
5.7 Discontinued Drugs for Cystic Fibrosis 30
5.8 Key Takeaway 30
6 Cystic Fibrosis: Implications for the Future Market Competition 31
7 Cystic Fibrosis: Future Players in the Cystic Fibrosis Market 32
7.1 Introduction 32
7.2 Cystic Fibrosis Foundation Therapeutics, Inc. 32
7.2.1 Overview 32
7.2.2 Cystic Fibrosis Portfolio 33
7.2.3 Cystic Fibrosis Pipeline Portfolio 34
7.3 Pharmaxis Ltd 35
7.3.1 Overview 35
7.3.2 Respiratory Portfolio 35
7.3.3 Cystic Fibrosis Pipeline Portfolio 36
7.4 Gilead Sciences, Inc 36
7.4.1 Overview 36
7.4.2 Respiratory Portfolio 37
7.4.3 Cystic Fibrosis Pipeline Portfolio 37
7.5 Vertex Pharmaceuticals, Inc 38
7.5.1 Overview 38
7.5.2 Respiratory Portfolio 38
7.5.3 Cystic Fibrosis Pipeline Portfolio 38
7.6 AstraZeneca 40
7.6.1 Overview 40
7.6.2 Respiratory Portfolio 40
7.6.3 Cystic Fibrosis Pipeline Portfolio 41
7.7 PARI Pharma 41
7.7.1 Overview 41
7.7.2 Respiratory Portfolio 41
7.7.3 Cystic Fibrosis Pipeline Portfolio 41
8 Cystic Fibrosis: Appendix 42
8.1 Market Definitions 42
8.2 Scope of Pipeline Research 42
8.3 Abbreviations 42
8.4 Research Methodology 43
8.4.1 Coverage 44
8.4.2 Secondary Research 44
8.4.3 Forecasting 45
8.4.4 Primary Research 48
8.4.5 Expert Panel validation 48
8.5 Contact Us 48
8.6 Disclaimer 48
8.7 Sources 49
[Fade out table of contents]

LIST OF TABLES

1.1 List of Tables
Table 1: Cystic Fibrosis Therapeutics Market, Global, Revenue ($m), 2001–2009 8
Table 2: Cystic Fibrosis Therapeutics Market, Global, Forecast Revenue ($m), 2009–2017 9
Table 3: Major Marketed Products Analysis in Cystic Fibrosis Therapeutics Market, 2010 17
Table 4: Cystic Fibrosis – Most Promising Drugs Under Clinical Development, 2010 20
Table 5: Cystic Fibrosis – Phase III Clinical Pipeline, 2010 25
Table 6: Cystic Fibrosis – Phase II Clinical Pipeline, 2010 26
Table 7: Cystic Fibrosis – Phase I Clinical Pipeline, 2010 28
Table 8: Cystic Fibrosis – Preclinical Pipeline, 2010 29
Table 9: Cystic Fibrosis – Discovery Pipeline, 2010 29
Table 10: Discontinued Drugs for Cystic Fibrosis, 2010 30
Table 11: CFFT – Cystic Fibrosis Marketed Products, 2010 33
Table 12: CFFT – Cystic Fibrosis Pipeline Portfolio, 2010 33
Table 13: Pharmaxis Ltd – Respiratory Marketed Product, 2010 35
Table 14: Pharmaxis Ltd – Respiratory Pipeline Portfolio, 2010 35
Table 15: Gilead Sciences, Inc – Respiratory Pipeline Portfolio, 2010 37
Table 16: Vertex Pharmaceuticals Inc – Respiratory Pipeline Portfolio, 2010 38
Table 17: AstraZeneca – Respiratory Marketed Products, 2010 40
Table 18: AstraZeneca – Respiratory Pipeline Portfolio, 2010 40
Table 19: Pari Pharma – Respiratory Marketed Products, 2010 41
Table 20: Pari Pharma – Respiratory Pipeline Portfolio, 2010 41

LIST OF FIGURES

1.2 List of Figures
Figure 1: Cystic Fibrosis Therapeutics Market, Global, Revenues ($m), 2001–2009 8
Figure 2: Cystic Fibrosis Therapeutics Market, Global, Forecast Revenues ($m), 2009–2017 9
Figure 3: Opportunity and Unmet Need in Cystic Fibrosis Market, 2010 11
Figure 4: Strategic Competitor Assessment of the Major Marketed Products in Cystic Fibrosis, 2010 12
Figure 5: Technology Trends Analytic Framework of the Cystic Fibrosis Pipeline, 2010 19
Figure 6: Technology Trends Analytic Framework of the Cystic Fibrosis Pipeline – Description, 2010 20
Figure 7: Cystic Fibrosis – Clinical Pipeline by Mechanism of Action, 2010 24
Figure 8: Cystic Fibrosis – Pipeline by Phase of Clinical Development, 2010 25
Figure 9: Cystic Fibrosis – Implications for the Future Market Competition, 2010 31
Figure 10: Cystic Fibrosis Therapeutics – Clinical Pipeline by Company , 2010 32
Figure 11: GlobalData Methodology 44
Figure 12: GlobalData Market Forecasting Model 47
[Fade out list of tables / figures]